Slovenië - Sloveens - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

oktreotid - prašek in vehikel za suspenzijo s podaljšanim sproščanjem za injiciranje - oktreotid 10 mg / 1 viala - oktreotid

Slovenië - Sloveens - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

oktreotid - prašek in vehikel za suspenzijo s podaljšanim sproščanjem za injiciranje - oktreotid 20 mg / 1 viala - oktreotid

Slovenië - Sloveens - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

oktreotid - prašek in vehikel za suspenzijo s podaljšanim sproščanjem za injiciranje - oktreotid 30 mg / 1 viala - oktreotid

Europese Unie - Sloveens - EMA (European Medicines Agency)

pfizer europe ma eeig - somatrogon - growth and development - hipofiza in hypothalamic hormoni in analogi - indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone.

Europese Unie - Sloveens - EMA (European Medicines Agency)

ascendis pharma endocrinology division a/s - lonapegsomatropin - growth and development - hipofize in hipotalamični hormoni in analogi - growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [ghd]),.

Europese Unie - Sloveens - EMA (European Medicines Agency)

amryt pharmaceuticals dac - octreotide acetate - acromegaly - hipofize in hipotalamični hormoni in analogi - mycapssa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.

Europese Unie - Sloveens - EMA (European Medicines Agency)

astrazeneca ab - gefitinib - karcinom, pljučni pljuč - antineoplastična sredstva - iressa je indiciran za zdravljenje odraslih bolnikov z lokalno napredno ali metastatskim non-small-cell lung cancer z aktiviranjem mutacije od epidermalna-rast-faktor-receptor tirozin kinaza.

Europese Unie - Sloveens - EMA (European Medicines Agency)

astrazeneca ab - osimertinib mesilate - karcinom, pljučni pljuč - druga zdravila z delovanjem na novotvorbe agenti, protein kinaza inhibitorji - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.

Europese Unie - Sloveens - EMA (European Medicines Agency)

roche registration gmbh - alectinib hidroklorid - karcinom, pljučni pljuč - antineoplastična sredstva - alecensa kot monotherapy je določen za prvo linijo zdravljenja odraslih bolnikih z anaplastični limfom kinaza (alk)-pozitivno napredno non-small cell lung cancer (nsclc). alecensa kot monotherapy je indiciran za zdravljenje odraslih bolnikov z alkalno‑pozitivno napredno nsclc predhodno zdravljenih z crizotinib.

Europese Unie - Sloveens - EMA (European Medicines Agency)

mylan pharmaceuticals limited - gefitinib - karcinom, pljučni pljuč - antineoplastic agents, protein kinase inhibitors - gefitinib mylan je označen kot monotherapy za zdravljenje odraslih bolnikov z lokalno napredno ali metastatskim non‑small cell lung cancer (nsclc) z aktiviranjem mutacije z egfr‑tk.